Oral chemotherapy candidate utidelone moves to human testing for advanced cancers

NCT ID NCT05700084

Ongoing Disease control Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This early-stage trial evaluates the safety, tolerability, and how well the body absorbs utidelone in capsule form for people with advanced solid tumors, including metastatic breast cancer. The study has three parts: finding the safest dose, comparing the capsule to the injected version, and testing the capsule combined with another chemotherapy drug. The goal is to determine if an oral version of utidelone could be a viable treatment option.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Utidelone (capsule form)
What this could lead to: If successful, this could lead to a more convenient oral version of utidelone for treating advanced solid tumors, potentially improving patient quality of life.
What could go wrong: This is an early phase 1 trial with a small number of participants, so safety and effectiveness are not yet established. Side effects and dose-limiting toxicities are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast carcinoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Show contact details

Locations

Cancer Hospital Chinese Academy of Medical Sciences

Beijing, China
Cancer Hospital of Shandong First Medical University

Jinan, China
LiaoNing Cancer Hospital&Institute

Shenyang, China
Renji Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, China
Sichuan Cancer Hospital

Chengdu, China
Sun Yat-sen University Cancer Center

Guangzhou, China
The Fifth Medical Center of Chinese PLA General Hospital

Beijing, China
The First Affiliated Hospital of XI'an JiaoTong University

Xi'an, China
The Fourth Hospital of Hebei Medical University

Shijiazhuang, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.